Navigation Links
MHRA Completes Review of CTA and Issues Notice of Acceptance for BMN 673 for Genetically-Defined Cancers
Date:12/2/2010

NOVATO, Calif., Dec. 2, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for BMN 673 for genetically-defined cancers.  The company expects to initiate a Phase 1/2 trial by the first quarter of 2011.

"BMN 673 has been proven to be highly active in mouse xenograft models of human cancer and appears to have superior potency, selectivity, and bioavailability as compared to other products in development," said Hank Fuchs, Chief Medical Officer of BioMarin.  "We are eager to get this trial underway and to identify specific tumor types that are more susceptible to treatment with BMN 673.  We have built a deep R&D pipeline and remain focused on successfully and expeditiously executing on the programs."

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase)
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Arbor Pharmaceuticals Completes $34.8 Million Financing
2. Aires Pharmaceuticals, Inc. Completes $20M Equity Financing and Signs an Option Agreement with a Major Pharmaceutical Company
3. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
4. Apollo Endosurgery Completes First-in-Human Cases With New OverStitch™ Endoscopic Suturing System
5. Boston Scientific Completes Acquisition of Asthmatx
6. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Highland Capital Management Announces 100% Ownership of American HomePatient, Completes Successful Public to Private Transition For Leading Provider of Home Respiratory Therapy
8. Incept BioSystems Completes First Human Clinical Trial of the SMART Start™ Embryo Culture System and Submits 510(k) Application to the FDA
9. InfraReDx Completes $21 Million Equity Financing
10. Ocular Therapeutix Completes Proof of Principle Study with Moxifloxacin-Loaded Punctum Plugs
11. Apollo Endosurgery Completes First Clinical Case with Newly-Launched FlexShears™ Endoscopic Scissors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 PharmaPoint: Type 1 Diabetes - ... Type 1 diabetes (T1D) is an autoimmune disease that ... that the body can no longer produce insulin. Over the ... at present, no other treatment can be offered to a ... insulin analogs with different times of action - long-acting as ...
(Date:5/27/2015)...  Precision Advisors ( www.precisionadvisors.com ), a Precision for ... Trends Study of 145 managed care executives. The study ... of big data and predictive analytics, but are not ... Health Information Technology for Economic and Clinical Health Act ... of electronic medical records (EMRs) by 2014. While a ...
(Date:5/27/2015)... May 27, 2015  LumiThera Inc., a developmental ... (PBM) treatment for ocular disorders and disease, announced ... Washington State Life Sciences Discovery Fund (LSDF) ... of the LSDF matching grants worth $500,000 to ... subjects with dry age-related macular degeneration (AMD). ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 2Precision Advisors Digital Trends Study: Less Than Half of Managed Care Organizations Have Access to Electronic Medical Records Data 3LumiThera Receives LSDF Commercialization Grant Award 2
... New Somatropin Formulation Demonstrate Advantages ... Over Existing Once-Daily ... Nottingham, UK-based speciality pharmaceuticals,company, today announced that the successful ... the synthetic human growth,hormone (hGH) somatropin. Trials demonstrated therapeutic ...
... released by The Philadelphia AIDS Consortium:, WHO: ... its network of eleven (11) community-based organization,sites located ... 30 AmeriCorps ACTS members working throughout New,Jersey, Delaware ... 9 a.m. until Noon; Media Focused,Event 10:30 - ...
Cached Medicine Technology:Critical Pharmaceuticals Enter Sustained Release hGH Arena 2Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2
(Date:5/27/2015)... The Case Management Society of ... provide CMSA's Career and Knowledge Pathways educational program ... strengthen the case/care management workforce by offering aptitude ... mutually beneficial agreement provides Medix, a workforce solutions ... in the healthcare, scientific and IT industries, access ...
(Date:5/27/2015)... SAN DIEGO, May 27, 2015 – Memorial Hospital, ... provider along the Gulf Coast to pioneer a ... partnership with MD Revolution, a digital care management ... that enables healthcare providers to easily meet Medicare’s ... user-friendly program is designed to improve patient engagement, ...
(Date:5/27/2015)... 2015 CompanionDx announced that ... genomic analysis in personalized cancer therapy: Non-small cell lung ... Society of Clinical Oncology (ASCO) as part of their ... , The molecular and clinical data used for the ... database. The study reports improved patient outcomes from a ...
(Date:5/27/2015)... IL (PRWEB) May 27, 2015 On ... North-based advertising agency, will partner with LifeSource to host ... event will take place in a LifeSource donor coach ... a.m. to 4:00 p.m. , Demand for whole blood ... in Illinois, during the summer months. LifeSource requires approximately ...
(Date:5/27/2015)... Dallas, Texas (PRWEB) May 27, 2015 ... on the current state of the Omega-3 industry. ... industry including definitions, classifications, applications and industry chain ... the international markets including development trends, competitive landscape ... Products, Gc Rieber Oils, Camanchaca Fishing Company, Seadragon ...
Breaking Medicine News(10 mins):Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 2Health News:Memorial Hospital Selects MD Revolution's Digital Health Platform to Deliver a New Form of Chronic Care Management 3Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 2Health News:CompanionDx® Analyzes Non-small Cell Lung Cancer Data for Personalized Cancer Therapy 3Health News:Donate Your Break and Save Lives at the River North Blood Drive 2Health News:Omega-3 Market: Global 2015 Analysis & 2020 Forecasts on Market Size 2
... The number of heat-related deaths is underestimated and underreported ... study published in Biomedical Market Newsletter//(R). ,A ... of heat-related deaths is actually 54% higher than previously ... hyperthermia as a contributing cause of death increased by ...
... estimate of the repercussions of a potential flu pandemic showed ... the underprivileged nations, could pay// with their life. , ... infamous 1918 Spanish flu, which wiped out nearly 20 million ... of Public Health and the University of Queensland studied the ...
... pain are effective, a new review of studies has ... such as// depression and health-related quality of life, they ... ,“Because this analysis was both more inclusive and more ... to date that these interventions are helpful,” said psychologist ...
... eight year old cancer patient may be forced to undertake ... the painful radiotherapy. Having beaten the condition called Wilm’s Tumour ... been confronted by the tumour after a three year respite. ... attack has left the child with a poor quality of ...
... Journal of Neurology Neurosurgery and Psychiatry published a study which ... for treating wrinkled skin could ease writer’s cramp as well. ... hand, arms or fingers which causes pain. This can also ... with their other hand, but in one in four cases, ...
... recently published a study which proves that fish oil supplements ... ,The trial was done on 98 women who ... from 20th week of their pregnancy till the birth of ... not routinely eat more than two weekly portions of fish ...
Cached Medicine News:Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 2Health News:Psychological Treatments Improve Outcomes for Back Pain Sufferers 3Health News:Fish Oil Improves Toddler’s Hand-eye Coordinatio 2
25 mm blunt, double-edged blade. Flat handle....
For use with N4096 R, N4097 R and N4098 R. 18 mm wide x 167 mm long. Ten per package. Designated most popular model or size....
5 mm small, sharp, protected blade. Angled at 105 degrees. Flat handle. Designated most popular model or size....
4 mm blade. Bayonet. Flat handle....
Medicine Products: